Clavmaxxing and the clavstack

Clavmaxxing is the community term for running the clavstack — the four research peptides most associated with Clavicular's publicly discussed protocol. It follows the same construction as the other coined maxxing terms in this catalogue (cutmaxxing, healmaxxing, bulkmaxxing), except those describe a goal and this one describes a source. Someone clavmaxxing is not pursuing a distinct outcome; they are researching a specific named grouping of compounds.

That distinction matters because it sets the boundary of the term. Clavmaxxing does not imply a dose, a cycle length, an order of operations, or a result. It describes which vials are on the bench and nothing beyond that. The word travels well in discussion precisely because it compresses a four-compound list into one token — but the compression is descriptive shorthand, not a protocol anyone publishes or endorses.

The clavstack is four compounds spread across three catalogue categories. Retatrutide sits under Cutmaxxing because its mechanism is metabolic — triple-agonist action on GLP-1, GIP, and glucagon receptors. BPC-157 and TB-500 both sit under Healmaxxing because both are tissue-repair peptides that appear together in published research on muscle, tendon, and gut barrier work. CJC-1295 No DAC sits under Bulkmaxxing because GHRH receptor activation affects pituitary growth-hormone release rather than fat metabolism or tissue repair directly.

That spread is the whole logic of the grouping. The clavstack covers three separate reasons a researcher comes to the catalogue without any two compounds overlapping, which is why the four cluster in public discussion instead of being argued over as alternatives. Someone clavmaxxing across all four is not paying twice for the same effect class; someone running only two is making a choice about which mechanism to prioritise first. Neither arrangement constitutes a recommended sequence or dose — it is simply how the four compounds' catalogue positions fall.